Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of California
mi
from
Irvine, CA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of California
mi
from
Irvine, CA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Movement Disorders Center
mi
from
Englewood, CO
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Movement Disorders Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of South Florida
mi
from
Tampa, FL
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Health Research & Education Institute
mi
from
Honolulu, HI
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Health Research & Education Institute
mi
from
Honolulu, HI
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Kentucky Medical Center
mi
from
Lexington, KY
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
LSU Health Science Center
mi
from
Shreveport, LA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
LSU Health Science Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Maryland
mi
from
Baltimore, MD
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Michigan State University
mi
from
East Lansing, MI
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Michigan State University
mi
from
East Lansing, MI
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Struthers Parkinson's Center
mi
from
Golden Valley, MN
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Struthers Parkinson's Center
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Nebraska Medical Center
mi
from
Omaha, NE
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Nevada School of Medicine
mi
from
Las Vegas, NV
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Nevada School of Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Atlantic Neuroscience Institute
mi
from
Summit, NJ
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Atlantic Neuroscience Institute
mi
from
Summit, NJ
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Albany Medical College
mi
from
Albany, NY
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Albany Medical College
mi
from
Albany, NY
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Health Quest Kingston
mi
from
Kingston, NY
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Health Quest Kingston
mi
from
Kingston, NY
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Sentara Neurology Specialists
mi
from
Virginia Beach, VA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Sentara Neurology Specialists
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Booth Gardner Parkinson's Care Center
mi
from
Kirkland, WA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Booth Gardner Parkinson's Care Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center
mi
from
Houston, TX
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
University of Calgary
mi
from
Calgary,
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
Efficacy of Isradipine in Early Parkinson Disease
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact
Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact
Status: Enrolling
Updated:  12/31/1969
VA Portland Health Care System (VAPORHCS)
mi
from
Portland, OR
Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact
Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact
Status: Enrolling
Updated: 12/31/1969
VA Portland Health Care System (VAPORHCS)
mi
from
Portland, OR
Click here to add this to my saved trials
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
A Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
A Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Telemedicine Intervention to Improve Cognitive Function
A Telemedicine Intervention to Improve Cognitive Function in Patients With PD
Status: Enrolling
Updated:  12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Telemedicine Intervention to Improve Cognitive Function
A Telemedicine Intervention to Improve Cognitive Function in Patients With PD
Status: Enrolling
Updated: 12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
Exercise Targeting Cognitive Impairment in Parkinson's Disease
Exercise Targeting Cognitive Impairment in Parkinson's Disease
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Exercise Targeting Cognitive Impairment in Parkinson's Disease
Exercise Targeting Cognitive Impairment in Parkinson's Disease
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)
Status: Enrolling
Updated:  12/31/1969
Acorda Investigational Site
mi
from
Scottsdale, AZ
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)
Status: Enrolling
Updated: 12/31/1969
Acorda Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials